Literature DB >> 10412892

Formulation of controlled release microspheres containing nicardipine: the role of pharmacokinetic modeling and computer simulation.

A Mrhar1, M Bogataj, I Grabnar, R Karba.   

Abstract

Nicardipine is an antihypertensive drug of the dihydropyridine series. It has high solubility in an acidic and low solubility in an alkaline medium. It is rapidly absorbed, extensively presystemically metabolized and excreted in the urine and faeces, mainly as inactive metabolites. Since the duration of its action can be extended by prolonging the absorption interval, the design of controlled release formulation is reasonable. The aim of the present study was to prepare microspheres which would release nicardipine at a decreased rate in gastric and increased rate in intestinal juice during a 12 h interval. Pharmacokinetic modeling based on compartment analysis and supported by analog computer and digital simulation technique showed that the target steady state peak plasma concentrations of 32 microg/l and trough plasma concentration of 7 microg/l would be maintained if nicardipine were incorporated in a formulation releasing the drug as follows: 25% after 1 h, 40% after 2 h, 65% after 4 h, 80% after 6 h, 90% after 8 h and 100% by 12 h. Microspheres have been prepared from hydroxypropylmethylcellulose phthalate polymer using the solvent evaporation method. Drug content, scanning electron micrographs, particle size distribution and dissolution profile were determined. In vitro nicardipine release was described by a biphasic square root of time kinetics and was in accordance with the above values relating to the dissolution. Furthermore, a composed first-pass pharmacokinetic model with derived release function as an input was developed to predict nicardipine plasma concentrations after single- and 12 h multiple-dosage-regimen scheme administration of controlled release microspheres.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412892     DOI: 10.1007/BF03190011

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  12 in total

1.  Pharmacokinetics of nicardipine following oral and intravenous administration in man.

Authors:  D J Graham; R J Dow; D Freedman; E Mroszczak; T Ling
Journal:  Postgrad Med J       Date:  1984       Impact factor: 2.401

2.  Effects on casual and 24-h ambulatory blood pressure of slow-release nicardipine and chlorthalidone in arterial essential hypertension: double-blind, crossover study.

Authors:  A Celentano; M Galderisi; P Tammaro; G F Mureddu; M Garofalo; O de Divitiis
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1990-05

3.  Formulation and evaluation of vinylpyrrolidone/vinylacetate copolymer microspheres with griseofulvin.

Authors:  D Vojnovic; F Rubessa; M Bogataj; A Mrhar
Journal:  J Microencapsul       Date:  1993 Jan-Mar       Impact factor: 3.142

4.  Intravenous nicardipine for the treatment of severe hypertension.

Authors:  J D Wallin; M E Cook; L Blanski; G S Bienvenu; G G Clifton; H Langford; P Turlapaty; A Laddu
Journal:  Am J Med       Date:  1988-09       Impact factor: 4.965

5.  Effects of long-term treatment with sustained-release nicardipine on left ventricular hypertrophy and function in patients with essential hypertension.

Authors:  T Sumimoto; K Hiwada; T Ochi; W Matsubara; T Joh; Y Imamura
Journal:  J Clin Pharmacol       Date:  1994-03       Impact factor: 3.126

6.  Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. IV Nicardipine Study Group.

Authors: 
Journal:  Chest       Date:  1991-02       Impact factor: 9.410

Review 7.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

8.  The metabolism and pharmacokinetics of nicardipine hydrochloride in man.

Authors:  D J Graham; R J Dow; D J Hall; O F Alexander; E J Mroszczak; D Freedman
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

9.  Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. The EOL Research Group.

Authors:  J P Boissel; O Meillard; E Perrin-Fayolle; T Ducruet; Y Alamercery; P Sassano; R Benghozi
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

10.  Nicardipine: pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers.

Authors:  C Thuillez; M Gueret; P Duhaze; F Lhoste; J R Kiechel; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

View more
  1 in total

1.  Pathways of paracetamol absorption from layered excipient suppositories: artificial intelligence approach.

Authors:  A Belic; I Grabnar; R Karba; A Mrhar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.